Last reviewed · How we verify
NCT06680882: AAS
The Effect of Non-invasive Auricular Acupoint Stimulation on Slow Transmission Constipation
Phase 2 trial testing Auricular Acupoint Stimulation +prucapride in Slow Transmission Constipation in 60 participants. Not yet recruiting.
7 November 2024
Quick facts
| Lead sponsor | The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 7 November 2024 |
| Primary completion | 7 November 2024 |
| Estimated completion | 1 November 2025 |
Drugs / interventions tested
- Auricular Acupoint Stimulation +prucapride
- prucapride — full drug profile →
Conditions studied
- Slow Transmission Constipation — all drugs for Slow Transmission Constipation →
Sponsor
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Who can join
Adults 40 to 75, any sex, with Slow Transmission Constipation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective To examine the therapeutic effect and safety of non-invasive auricular acupoint stimulation application on patients with slow transmission constipation. Methods In a randomized clinical trial, 60 patients diagnosed with slow transit constipation (STC), ranging in age from 40 to 75 years, were allocated into two distinct cohorts: a study group and a control group. The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride, while the control group, also consisting of 30 patients, was administered prucapride as a monotherapy. To assess the efficacy of the interventions, various parameters were monitored, including serum levels of Neuropeptide Y (NPY), nitric oxide (NO), fecal water content, and gastrointestinal (GI) transit. The comparative therapeutic outcomes were determined by calculating symptom scores.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06680882
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07495046 — Low Excision and High Suspension Hemorrhoidectomy Versus Conventional Milligan-Morgan Hemorrhoidectomy for Grade III-IV · NA · not yet recruiting
- NCT07128953 — Study on the Mechanism of Zuoqing San Promoting Postoperative Wound Healing of Anal Fistula by Inhibiting ROS-dependent · EARLY_PHASE1 · enrolling by invitation
- NCT06667934 — Clinical Trial of Zuoqing SAN in Treating Ulcerative Colitis · Phase 1, PHASE2 · not yet recruiting
- NCT06663527 — Compound Phellodendron Decoction May Promote Wound Healing After Anal Fistulotomy · NA · completed
- NCT06660680 — The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: A Randomized Controlled · Phase 3 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06680882 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06680882.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing